These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38260385)

  • 21. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
    Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
    Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
    Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
    Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
    Ray U; Orlowski RZ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Belantamab Mafodotin on Primary Myeloma-Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells.
    Matula Z; Uher F; Vályi-Nagy I; Mikala G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
    Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
    Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
    Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
    Ehsan H; Robinson M; Voorhees PM; Cassetta K; Borden S; Atrash S; Bhutani M; Varga C; Pineda-Roman M; Friend R; Paul BA
    Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
    Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
    Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
    Joseph NS; Tai YT; Anderson KC; Lonial S
    Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody Drug Conjugates in Multiple Myeloma.
    Ferreri CJ; Lee HC
    Cancer J; 2022 Nov-Dec 01; 28(6):488-495. PubMed ID: 36383912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
    Trudel S; McCurdy A; Louzada ML; Parkin S; White D; Chu MP; Kotb R; Mian H; Othman I; Su J; Khan A; Gul E; Reece D
    Nat Med; 2024 Feb; 30(2):543-551. PubMed ID: 38177852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How I treat relapsed and/or refractory multiple myeloma.
    Lee HC; Cerchione C
    Hematol Rep; 2020 Sep; 12(Suppl 1):8955. PubMed ID: 33042504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
    Munawar U; Theuersbacher J; Steinhardt MJ; Zhou X; Han S; Nerreter S; Vogt C; Kurian S; Keller T; Regensburger AK; Teufel E; Mersi J; Bittrich M; Seifert F; Haider MS; Rasche L; Hillenkamp J; Einsele H; Kampik D; Kortüm KM; Waldschmidt JM
    Haematologica; 2024 Nov; 109(11):3670-3680. PubMed ID: 38572568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
    Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
    Acta Haematol; 2024; 147(4):493-498. PubMed ID: 34839282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
    Xing L; Wang S; Liu J; Yu T; Chen H; Wen K; Li Y; Lin L; Hsieh PA; Cho SF; An G; Qiu L; Kinneer K; Munshi N; Anderson KC; Tai YT
    Clin Cancer Res; 2021 Oct; 27(19):5376-5388. PubMed ID: 34301753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.